Epigallocatechin Gallate (EGCG) Suppresses Growth and Tumorigenicity in Breast Cancer Cells by Downregulation of MiR-25

Overview

Journal Bioengineered

Date 2019 Aug 22

PMID 31431131

Citations 62

Authors

Lingling Zan

Qingfeng Chen

Lei Zhang

XiaoNa Li

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to investigate the anticancer effects and potential mechanisms of polyphenol epigallocatechin-3-gallate (EGCG) on breast cancer MCF-7 cells and . Our results showed that EGCG significantly inhibited MCF-7 cell viability in a time- and dose-dependent manner. Flow cytometry analysis indicated that EGCG induced apoptosis and disrupted cell cycle progression at G2/M phase. Moreover, EGCG inhibited miR-25 expression and increased PARP, pro-caspase-3 and pro-caspase-9 at protein levels. Restoration of miR-25 inhibited EGCG-induced cell apoptosis. Furthermore, EGCG suppressed tumor growth by downregulating the expression of miR-25 and proteins associated with apoptosis, which was further confirmed by a reduction of Ki-67 and increase of pro-apoptotic PARP expression as determined by immunohistochemistry staining. These findings indicate that EGCG possesses chemopreventive potential in breast cancer which may serve as a promising anticancer agent for clinical applications.

Citing Articles

Exploring natural products as apoptosis modulators in cancers: insights into natural product-based therapeutic strategies.

Utpal B, Bouenni H, Zehravi M, Sweilam S, Mortuza M, Arjun U Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40014131 DOI: 10.1007/s00210-025-03876-8.

Green Tea Components: In Vitro and In Vivo Evidence for Their Anticancer Potential in Colon Cancer.

Randisi F, Perletti G, Marras E, Gariboldi M Cancers (Basel). 2025; 17(4).

PMID: 40002218 PMC: 11853328. DOI: 10.3390/cancers17040623.

Nanotechnology-driven EGCG: bridging antioxidant and therapeutic roles in metabolic and cancer pathways.

Esmaeili Z, Shavali Gilani P, Khosravani M, Motamedi M, Maleknejad S, Adabi M Nanomedicine (Lond). 2025; 20(6):621-636.

PMID: 39924937 PMC: 11881875. DOI: 10.1080/17435889.2025.2462521.

Role of Epigallocatechin Gallate in Selected Malignant Neoplasms in Women.

Markowska A, Antoszczak M, Markowska J, Huczynski A Nutrients. 2025; 17(2).

PMID: 39861342 PMC: 11767294. DOI: 10.3390/nu17020212.

Epigallocatechin-3-gallate therapeutic potential in human diseases: molecular mechanisms and clinical studies.

Alam M, Gulzar M, Akhtar M, Rashid S, Zulfareen , Tanuja Mol Biomed. 2024; 5(1):73.

PMID: 39725830 PMC: 11671467. DOI: 10.1186/s43556-024-00240-9.

References

Li S, Wu L, Feng J, Li J, Liu T, Zhang R . In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity. Sci Rep. 2016; 6:28479. PMC: 4923908. DOI: 10.1038/srep28479. View

Li T, Zhao N, Lu J, Zhu Q, Liu X, Hao F . Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways. Bioengineered. 2019; 10(1):282-291. PMC: 6650192. DOI: 10.1080/21655979.2019.1632669. View

Chu P, Tsai S, Ko H, Wu C, Lin Y . Co-Delivery of Natural Compounds with a Dual-Targeted Nanoparticle Delivery System for Improving Synergistic Therapy in an Orthotopic Tumor Model. ACS Appl Mater Interfaces. 2019; 11(27):23880-23892. DOI: 10.1021/acsami.9b06155. View

Hesari A, Azizian M, Darabi H, Nesaei A, Hosseini S, Salarinia R . Expression of circulating miR-17, miR-25, and miR-133 in breast cancer patients. J Cell Biochem. 2018; 120(5):7109-7114. DOI: 10.1002/jcb.27984. View

Tang Q, Zhong H, Xie F, Xie J, Chen H, Yao G . Expression of miR-106b-25 induced by salvianolic acid B inhibits epithelial-to-mesenchymal transition in HK-2 cells. Eur J Pharmacol. 2014; 741:97-103. DOI: 10.1016/j.ejphar.2014.07.051. View

Ahmad N, Feyes D, Nieminen A, Agarwal R, Mukhtar H . Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst. 1997; 89(24):1881-6. DOI: 10.1093/jnci/89.24.1881. View

Zhu Y, Huang Y, Liu M, Yan Q, Zhao W, Yang P . Epigallocatechin gallate inhibits cell growth and regulates miRNA expression in cervical carcinoma cell lines infected with different high-risk human papillomavirus subtypes. Exp Ther Med. 2019; 17(3):1742-1748. PMC: 6364235. DOI: 10.3892/etm.2018.7131. View

Liao S, Umekita Y, Guo J, Kokontis J, Hiipakka R . Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett. 1995; 96(2):239-43. DOI: 10.1016/0304-3835(95)03948-v. View

La X, Zhang L, Li Z, Li H, Yang Y . (-)-Epigallocatechin Gallate (EGCG) Enhances the Sensitivity of Colorectal Cancer Cells to 5-FU by Inhibiting GRP78/NF-κB/miR-155-5p/MDR1 Pathway. J Agric Food Chem. 2019; 67(9):2510-2518. DOI: 10.1021/acs.jafc.8b06665. View

10.

Luo K, Chen W, Lung W, Wei X, Cheng B, Cai Z . EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-κB and MMP-9. J Nutr Biochem. 2017; 41:56-64. DOI: 10.1016/j.jnutbio.2016.12.004. View

11.

Cao Y, Cao R . Angiogenesis inhibited by drinking tea. Nature. 1999; 398(6726):381. DOI: 10.1038/18793. View

12.

Yamada S, Tsukamoto S, Huang Y, Makio A, Kumazoe M, Yamashita S . Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression by activating 67-kDa laminin receptor signaling in melanoma cells. Sci Rep. 2016; 6:19225. PMC: 4709792. DOI: 10.1038/srep19225. View

13.

Wu D, Liu Z, Li J, Zhang Q, Zhong P, Teng T . Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway. Cancer Cell Int. 2019; 19:43. PMC: 6394055. DOI: 10.1186/s12935-019-0762-9. View

14.

Jiang P, Xu C, Chen L, Chen A, Wu X, Zhou M . Epigallocatechin-3-gallate inhibited cancer stem cell-like properties by targeting hsa-mir-485-5p/RXRα in lung cancer. J Cell Biochem. 2018; 119(10):8623-8635. DOI: 10.1002/jcb.27117. View

15.

Wu X, Zeng R, Wu S, Zhong J, Yang L, Xu J . Comprehensive expression analysis of miRNA in breast cancer at the miRNA and isomiR levels. Gene. 2014; 557(2):195-200. DOI: 10.1016/j.gene.2014.12.030. View

16.

Wei R, Mao L, Xu P, Zheng X, Hackman R, Mackenzie G . Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models. Food Funct. 2018; 9(11):5682-5696. PMC: 7480214. DOI: 10.1039/c8fo01397g. View

17.

Chen Y, Wang X, Zhang Q, Zhu J, Li Y, Xie C . (-)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway. Nutrients. 2017; 9(6). PMC: 5490551. DOI: 10.3390/nu9060572. View

18.

Caiazza C, Mallardo M . The Roles of miR-25 and its Targeted Genes in Development of Human Cancer. Microrna. 2016; 5(2):113-119. DOI: 10.2174/2211536605666160905093429. View

19.

Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T . MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 2014; 5(16):7013-26. PMC: 4196180. DOI: 10.18632/oncotarget.2192. View

20.

Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y . Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res. 1998; 89(3):254-61. PMC: 5921805. DOI: 10.1111/j.1349-7006.1998.tb00556.x. View